Three-dimensional imaging could provide equivalent image quality to 2D acquisitions in T2-weighted imaging of the prostate at 3T.
Three-dimensional acquisitions provide equivalent image and lesion delineation quality, compared to 2D in T2-weighted imaging of the prostate, according to a study published in the journal European Radiology.
Researchers from Austria performed a prospective study to determine if 3D acquisitions could provide equivalent image quality, lesion delineation quality and PI-RADS v2 performance compared to 2D acquisitions in T2-weighted imaging of the prostate at 3 T.
One hundred fifty patients (mean age 63.7 years; mean PSA 7.2 ng/ml) participated in the study. Two uroradiologists independently rated image quality and lesion delineation quality using a five-point ordinal scale and assigned a PI-RADS score for 2D and 3D T2-weighted image data sets. Data were compared using visual grading characteristics (VGC) and receiver operating characteristics (ROC)/area under the curve (AUC) analysis.
The results demonstrated equivalent image and delineation quality, and PI-RADS v2 performance, compared to 2D in T2-weighted imaging of the prostate.
Reader 1/Reader 2
Image quality for 2D T2w
Mean score: 4.3 ± 0.81/Mean score:4.7 ± 0.83
Image quality for 3D T2w
Mean score: 4.3 ± 0.82/Mean score:4.7 ± 0.69
Lesion delineation for 2D T2w
4.16 ± 0.81/4.19 ± 0.92
Lesion delineation for 3D T2w
4.19 ± 0.94/4.27 ± 0.94
ROC analysis showed an equivalent performance for 2D (AUC 0.580–0.623) and 3D (AUC 0.576–0.629) T2w.
The researchers concluded that three-dimensional T2-weighted imaging could be used to considerably shorten prostate MRI protocols in clinical practice.
Can MRI-Based Deep Learning Improve Risk Stratification in PI-RADS 3 Cases?
January 30th 2025In external validation testing, a deep learning model demonstrated an average AUC of 87.6 percent for detecting clinically significant prostate cancer (csPCA) on prostate MRI for patients with PI-RADS 3 assessments.